A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 10 Nov 2025
At a glance
- Drugs Amlitelimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 06 Nov 2025 Status changed from active, no longer recruiting to discontinued (Sponsor decision, unrelated to safety concern).
- 10 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2024 According to a Sanofi media release, results expected in second half of 2024.